CONSTELLATION PHARMACEUTICALS INC (CNST) [Rocket]

In millions, except per share items	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16
	10-K	10-K	10-K	10-K	10-K
Revenues	124.9	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0
Gross profit	124.9	0.0	0.0	0.0	0.0
Gross margin	100.0%
Selling, general and administrative [+]	29.3	19.6	12.5	6.5	5.8
General and administrative	29.3	19.6	12.5	6.5	5.8
Research and development	95.5	66.5	48.8	32.6	27.9
Other operating expenses	124.8
EBITDA [+]	-124.2	-85.3	-60.7	-38.6	-33.5
EBITDA growth	45.6%	40.6%	57.2%	15.4%
EBITDA margin	-99.4%
Depreciation and amortization	0.6	0.8	0.6	0.5	0.2
EBIT [+]	-124.8	-86.1	-61.2	-39.1	-33.7
EBIT growth	45.0%	40.5%	56.7%	16.1%
EBIT margin	-99.9%
Non-recurring items [+]	0.0
Loss (gain) on sale of assets	0.0
Interest expense, net [+]	0.0	-0.5	-1.3	0.7	1.3
Interest expense	2.9	2.1	0.2	0.9	1.3
Interest income	2.9	2.6	1.5	0.2	0.1
Other income (expense), net [+]	-1.5			4.4	0.4
Gain (loss) on debt retirement	-1.5
Gain (loss) on derivative instruments				4.4	0.4
Pre-tax income	-126.3	-85.5	-59.9	-35.4	-34.5
Income taxes	0.0	0.0	0.0	0.0	0.0
Tax rate			0.0%	0.0%	0.0%
Net income	-126.4	-85.6	-59.9	-53.8	-49.5
Net margin	-101.2%

Basic EPS [+]	($2.81)	($3.04)	($5.00)	($56.10)	($53.19)
Growth	-7.4%	-39.2%	-91.1%	5.5%
Diluted EPS [+]	($2.81)	($3.04)	($5.00)	($56.10)	($53.19)
Growth	-7.4%	-39.2%	-91.1%	5.5%

Shares outstanding (basic) [+]	44.9	28.2	12.0	1.0	0.9
Growth	59.5%	134.9%	1150.4%	3.1%
Shares outstanding (diluted) [+]	44.9	28.2	12.0	1.0	0.9
Growth	59.5%	134.9%	1150.4%	3.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.